Search Within

Gopakumar Vasudeva Iyer

  1. "Deborah DeLair"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (1)
Groups
  1. Biostatistics Service (5)
  2. Department of Medicine (5)
  3. Early Drug Development Service (5)
  4. Epidemiology and Biostatistics (5)
  5. GDMT, Medicine (5)
  6. Genitourinary Oncology Service (5)

More Groups

People
  1. David Hyman (5)
  2. Deborah DeLair (5)
  3. Carol Aghajanian (4)
  4. Rachel Grisham (4)
  5. Alexia Iasonos (3)
  6. David Solit (3)

More People

Years
  1. 2017 (1)
  2. 2015 (1)
  3. 2014 (1)
  4. 2013 (2)
Publications
  1. Journal of Clinical Oncology (2)
  2. Cancer (1)
  3. International Journal of Gynecological Cancer (1)
  4. Nature Medicine (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Lippincott Williams & Wilkins (1)
  3. Nature Publishing Group (1)
  4. Wiley Blackwell (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Journal Article

    Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
    Nature Medicine (2017)

    Fulltext@MSK | Save
  • Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Sylvester, B. E.; Won, H.; McDermott, G.; DeLair, D.; Ramirez, R.; Yao, Z.; Shen, R. L.; Dao, F.; Bogomolniy, F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Hyman, D. M.; Aghajanian, C.
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save
  • Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Garg, K.; DeLair, D.; Hyman, D. M.; Zhou, Q.; Iasonos, A.; Berger, M. F.; Dao, F.; Spriggs, D. R.; more...
    Cancer (2013)

    Fulltext@MSK | Save